Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 2/20 | 0.74 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.74 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.74 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.74 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.74 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 12/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13555035 | 1.00 | PTGIR (0.74) | PTGIRPTGER1PTGER3PTGER2PTGDR | |
| SCHEMBL12951550 | 0.90 | PTGER3 (0.58) | PTGIRPTGER1PTGER3PTGER2PTGDR | |
| SCHEMBL4358 | 0.90 | PTGIR (0.72) | PTGIRPTGER1PTGER3PTGER2PTGDR | |
| SCHEMBL12951549 | 0.88 | PTGIR (0.80) | PTGIRPTGER1PTGER3PTGER2PTGDR | |
| SCHEMBL10636092 | 0.88 | PTGIR (0.80) | PTGIRPTGER1PTGER3PTGER2PTGDR | |
| SCHEMBL13386479 | 0.88 | PTGIR (0.80) | PTGIRPTGER1PTGER3PTGER2PTGDR | |
| SCHEMBL13386481 | 0.88 | PTGIR (0.80) | PTGIRPTGER1PTGER3PTGER2PTGDR | |
| SCHEMBL10345587 | 0.88 | PTGIR (0.80) | PTGIRPTGER1PTGER3PTGER2PTGDR | |
| SCHEMBL12951592 | 0.88 | PTGIR (0.74) | PTGIRPTGER1PTGER3PTGER2PTGDR | |
| SCHEMBL13555005 | 0.88 | PTGIR (0.74) | PTGIRPTGER1PTGER3PTGER2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270934-A1 | PROSTACYCLIN DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270934-A1 | PROSTACYCLIN DERIVATIVES | PTGIS, PTGIR, PTGER1 | PTGIR 2/4885PTGER1 3/4885PTGER3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.